“Early Changes in Patient-Relevant Endpoints in Three Tralokinumab Pivotal Phase 3 Trials (ECZTRA 1−3) in Adult Patients With Moderate-to-Severe Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s98, https://doi.org/10.25251/skin.4.supp.98.